Paris: French health authorities are advised to oppose the use of the Covid Moderna Jab for people under 30 years ago, after a national study confirmed a slight risk of heart inflammation associated with the MRNA vaccine.
Studies from EPI-Phare, independent drug safety research groups that work with the French government, confirmed previous findings – while noting cases rarely occurred and did not doubt the effectiveness of the shot.
It looked at all people in France aged 12 to 50 years hospitalized for myocarditis (heart muscle inflammation) or pericarditis (inflammation of the network around the heart) between May 15 and August 31 this year.
The results showed that vaccines from Pfizer and Moderna increased the risk of this disease within seven days of vaccination.
Risk, while low, higher in men under 30 years and especially after the second dose of modern vaccines, which found this study was responsible for around 132 cases of myocarditis per million doses given.
For Pfizer the results are almost 80 percent lower, with the number of cases per million doses estimated at 27.
In women under 30, Moderna may have caused 37 cases of myocarditis per million doses.
The risk of pericarditis is also greater after the second dose of moderna at the age of 30, with 18 cases per million doses given to young men.
There were no deaths among patients who were hospitalized with this disease after vaccination was reported.
The US has also postponed the approval of the Moderna Jab for young people, although last week they recommend the use of the Pfizer vaccine for children aged five to 11 after reviewing myocarditis risks.
Matthew Oster’s cardiologist, commented on the recommendation of the Pfizer at the time, said he was “far more worried” about the risk of Covid to young people than the risks caused by the vaccine.
Mahmoud Zureik, who heads epi-phare, echo sentiments.
“When you measure the effectiveness of vaccines against heavy cases of Covid-19 on existing risks but rarely occur …
vaccine value is undoubtedly,” he said.
France suggested against Moderna for under 30s for the risk of rare heart
